TY - JOUR
T1 - Chemotherapy Versus Chemotherapy Plus Chemoradiation as Preoperative Therapy for Resectable Gastric Adenocarcinoma
T2 - A Propensity Score-Matched Analysis of a Large, Single-Institution Experience
AU - Allen, Casey J.
AU - Blumenthaler, Alisa N.
AU - Smith, Grace L.
AU - Das, Prajnan
AU - Minsky, Bruce D.
AU - Blum, Mariela
AU - Ajani, Jaffer
AU - Mansfield, Paul F.
AU - Ikoma, Naruhiko
AU - Badgwell, Brian D.
N1 - Funding Information:
Prajnan Das: Honorarium-Adlai Nortye, Honorarium-MD Anderson Cancer Center Madrid Spain. Alisa Blumenthaler: My work is supported by a National Institute of Health T32 training grant (Grant Number T32 CA 009599), which provides funding support for research fellows in surgical oncology.
Funding Information:
This research was supported by the National Institutes of Health/National Cancer Institute under award number P30CA016672 and The No Stomach for Cancer Award for Gastric Cancer Research. The authors would like to acknowledge Erica Goodoff in Scientific Publications, Medical Research Library at MD Anderson Cancer Center for editing assistance.
Funding Information:
This research was supported by the National Institutes of Health/National Cancer Institute under award number P30CA016672 and The No Stomach for Cancer Award for Gastric Cancer Research. The authors would like to acknowledge Erica Goodoff in Scientific Publications, Medical Research Library at MD Anderson Cancer Center for editing assistance.
Publisher Copyright:
© 2020, Society of Surgical Oncology.
PY - 2021/2
Y1 - 2021/2
N2 - Background: We compared oncologic outcomes of patients who received neoadjuvant chemotherapy (CT) with those of patients who received neoadjuvant chemotherapy plus chemoradiation (CRT) for resectable gastric adenocarcinoma. Methods: We compared oncologic and survival outcomes of patients who received CT or CRT for gastric adenocarcinoma at our institution between July 1995 and July 2018. We analyzed propensity score–matched cohorts based on age, sex, race, tumor histologic characteristics, and clinical stage. Results: We identified 440 patients (mean age 61 ± 12 years, 62% male, 55% white); 345 (78%) received CRT, and 95 (22%) received CT. The propensity score-matched cohorts included 65 patients who received CT and 65 who received CRT. The CRT group had similar frequencies of R1 resection margins to the CT group (7.7% vs. 6.2%, p = 0.75) but significantly higher frequency of pathologic complete response (27.7% vs. 1.5%, p < 0.001). The CRT group had lower pathologic stages (p = 0.002). Median disease-free survival was 50.9 months (95% confidence interval [CI]: 4.7–97.2) in the CT group and 122.1 months (95% CI: 69.0–175.1) in the CRT group (p = 0.07). Median overall survival was 70.7 months (95% CI: 23.9–117.5) in the CT group and 122.1 months (95% CI: 68.7–175.4) in the CRT group (p = 0.21). Conclusions: Compared with CT, CRT for resectable gastric adenocarcinoma is associated with higher rates of pathologic complete response and subsequent lower final pathologic stage, but survival differences are not significant. Ongoing investigation is necessary to better determine the optimal neoadjuvant therapy and identify patients who receive optimal benefit from CRT. Level of Evidence: III.
AB - Background: We compared oncologic outcomes of patients who received neoadjuvant chemotherapy (CT) with those of patients who received neoadjuvant chemotherapy plus chemoradiation (CRT) for resectable gastric adenocarcinoma. Methods: We compared oncologic and survival outcomes of patients who received CT or CRT for gastric adenocarcinoma at our institution between July 1995 and July 2018. We analyzed propensity score–matched cohorts based on age, sex, race, tumor histologic characteristics, and clinical stage. Results: We identified 440 patients (mean age 61 ± 12 years, 62% male, 55% white); 345 (78%) received CRT, and 95 (22%) received CT. The propensity score-matched cohorts included 65 patients who received CT and 65 who received CRT. The CRT group had similar frequencies of R1 resection margins to the CT group (7.7% vs. 6.2%, p = 0.75) but significantly higher frequency of pathologic complete response (27.7% vs. 1.5%, p < 0.001). The CRT group had lower pathologic stages (p = 0.002). Median disease-free survival was 50.9 months (95% confidence interval [CI]: 4.7–97.2) in the CT group and 122.1 months (95% CI: 69.0–175.1) in the CRT group (p = 0.07). Median overall survival was 70.7 months (95% CI: 23.9–117.5) in the CT group and 122.1 months (95% CI: 68.7–175.4) in the CRT group (p = 0.21). Conclusions: Compared with CT, CRT for resectable gastric adenocarcinoma is associated with higher rates of pathologic complete response and subsequent lower final pathologic stage, but survival differences are not significant. Ongoing investigation is necessary to better determine the optimal neoadjuvant therapy and identify patients who receive optimal benefit from CRT. Level of Evidence: III.
UR - http://www.scopus.com/inward/record.url?scp=85088291486&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85088291486&partnerID=8YFLogxK
U2 - 10.1245/s10434-020-08864-1
DO - 10.1245/s10434-020-08864-1
M3 - Article
C2 - 32696305
AN - SCOPUS:85088291486
SN - 1068-9265
VL - 28
SP - 758
EP - 765
JO - Annals of surgical oncology
JF - Annals of surgical oncology
IS - 2
ER -